DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers

Information source: SCRI Development Innovations, LLC
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Neuroendocrine Carcinoma; Neuroendocrine

Intervention: Bevacizumab (Drug); Pertuzumab (Drug); Sandostatin LAR® Depot (Drug)

Phase: Phase 2

Status: Active, not recruiting

Sponsored by: SCRI Development Innovations, LLC

Official(s) and/or principal investigator(s):
Johanna C Bendell, S.B., M.D., Study Chair, Affiliation: SCRI Development Innovations, LLC


The purpose of this Phase II trial will be to define the activity of a VEGF inhibitor bevacizumab, HER1/HER2 inhibitor pertuzumab, and sandostatin for patients with advanced neuroendocrine cancers. In particular, the efficacy of bevacizumab and pertuzumab treatment is of great interest. The primary endpoint of this trial will be response rate. Toxicity and progression-free survival will be obtained and evaluated.

Clinical Details

Official title: Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Sandostatin for Patients With Advanced Neuroendocrine Cancers.

Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Determine overall response rate of patients with low grade neuroendocrine cancer when treated with the combination of bevacizumab, pertuzumab and sandostatin LAR®.

Secondary outcome: define the toxicity and safety

Detailed description:

- To determine overall response rate of patients with low grade neuroendocrine cancer

when treated with the combination of bevacizumab, pertuzumab and sandostatin LAR®.

- To determine the disease control rate (objective response + stable disease), time to

treatment progression, progression-free survival, and overall survival in patients with advanced low grade neuroendocrine cancer when treated with bevacizumab, pertuzumab and Sandostatin LAR® treatment.

- To define the toxicity and safety of the combination of bevacizumab, pertuzumab and

Sandostatin LAR® when used in patients with advanced low grade neuroendocrine cancer.


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria: 1. Patients with biopsy-proven advanced, unresectable or metastatic, well-differentiated (or low-grade) neuroendocrine carcinoma, including typical carcinoid, pancreatic islet cell and other well-differentiated neuroendocrine carcinomas. 2. Patients with documented evidence of disease progression. 3. Patients currently receiving or previously treated with single agent Sandostatin LAR® are eligible. 4. Patients must have >=1 unidimensional measurable lesion definable by MRI or CT scan. Disease must be measurable per RECIST version 1. 1 criteria. 5. Left Ventricular Ejection Fraction (LVEF) >=50% as determined by either ECHO or MUGA <=6 weeks prior to study entry. 6. An ECOG Performance Status of 0-2. 7. Laboratory values as follows:

- ANC >=1500/μL

- Hgb >=9 g/dL

- Platelets >=100,000/μL

- AST/SGOT <=2. 5 x ULN or <=5. 0 x ULN in patients with liver metastases

- ALT/SGPT <=2. 5 x ULN or <=5. 0 x ULN in patients with liver metastases

- Bilirubin <=1. 5 x ULN

- Creatinine <=2. 0 mg/dL or calculated creatinine clearance >=50 mL/min

8. Patients >=18 years of age. 9. Patients must have a life expectancy >12 weeks. 10. Patient must be accessible for treatment and follow-up. 11. Women of childbearing potential must have a negative serum or urine pregnancy test performed <=7 days prior to start of treatment. Women of childbearing potential must use effective birth control measures during treatment. If a woman becomes pregnant or suspects she is pregnant while participating in this study, she must agree to inform her treating physician immediately. 12. Patients must be able to understand the nature of the study and give written informed consent, and comply with study requirements Exclusion Criteria: 1. Patients with poorly differentiated neuroendocrine carcinoma, highgrade neuroendocrine carcinoma, adenocarcinoid, goblet cell carcinoid, atypical carcinoid, anaplastic carcinoid, and small cell carcinoma are not eligible. 2. Previous treatment with VEGF or EGFR inhibitors. 3. Cytotoxic chemotherapy, immunotherapy or radiotherapy <=4 weeks prior to study entry. 4. History or known presence of central nervous system (CNS) metastases. 5. Patients who have had a major surgical procedure (not including mediastinoscopy), open biopsy, or significant traumatic injury <=4 weeks prior to beginning treatment. 6. Female patients who are pregnant or lactating. 7. History of hypersensitivity to active or inactive excipients of any component of treatment (bevacizumab, sandostatin, and/or pertuzumab). 8. Patients with proteinuria at screening as demonstrated by urine dipstick for proteinuria >=2+ (patients discovered to have >=2+ proteinuria on dipstick urinalysis at baseline should undergo a 24-hour urine collection, and must demonstrate <=1 g of protein/24 hours to be eligible). 9. Patients with a serious non-healing wound, active ulcer, or untreated bone fracture. 10. Patients with evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation). 11. Patients with history of hematemesis or hemoptysis (defined as having bright red blood of ½ teaspoon or more per episode) <=1 month prior to study enrollment. 12. History of myocardial infarction or unstable angina <=6 months prior to beginning treatment. 13. Inadequately controlled hypertension (defined as systolic blood pressure >150 mmHg and /or diastolic blood pressure >100 mmHg while on antihypertensive medications). Initiation of antihypertensive agents is permitted provided adequate control is documented at least 1 week prior to Day of study treatment. 14. New York Heart Association (NYHA) grade II or greater congestive heart failure (CHF). 15. Serious cardiac arrhythmia requiring medication. 16. Significant vascular disease (e. g., aortic aneurysm requiring surgical repair, or recent peripheral arterial thrombosis) <=6 months prior to Day 1 of treatment. 17. History of stroke or transient ischemic attack <=6 months prior to beginning treatment. 18. Any prior history of hypertensive crisis or hypertensive encephalopathy. 19. History of abdominal fistula or gastrointestinal perforation <=6 months prior to Day 1 of beginning treatment. 20. Concurrent severe, intercurrent illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements. 21. Any known positive test for human immunodeficiency virus, hepatitis C virus or acute or chronic hepatitis B infection. 22. Mental condition that would prevent patient comprehension of the nature of, and risk associated with, the study. 23. Use of any non-approved or investigational agent <=28 days prior to administration of the first dose of study drug. Patients may not receive any other investigational or anti-cancer treatments while participating in this study. 24. Past or current history of neoplasm other than the entry diagnosis with the exception of treated non-melanoma skin cancer or carcinoma in situ of the cervix, or other cancers cured by local therapy alone and a DFS >=5 years. 25. Infection requiring IV antibiotics.

Locations and Contacts

Florida Cancer Specialists, Fort Myers, Florida 33901, United States

Florida Hospital Cancer Institute, Orlando, Florida 32804, United States

Medical Oncology Associates of Augusta, Augusta, Georgia 30901, United States

Baptist Medical Center East, Louisville, Kentucky 40207, United States

Grand Rapids Oncology Program, Grand Rapids, Michigan 49503, United States

Research Medical Center, Kansas City, Missouri 64132, United States

Hematology-Oncology Associates of Northern NJ, Morristown, New Jersey 07960, United States

Oncology Hematology Care, Inc, Cincinnati, Ohio 45242, United States

Tennessee Oncology Associates, Nashville, Tennessee 37203, United States

Additional Information

Starting date: May 2010
Last updated: September 10, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017